Form 8-K - Current report:
SEC Accession No. 0001213900-24-113158
Filing Date
2024-12-27
Accepted
2024-12-27 17:10:07
Documents
15
Period of Report
2024-12-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226161-8k_citius.htm   iXBRL 8-K 24492
2 PRESS RELEASE, DATED DECEMBER 27, 2024 ea022616101ex99-1_citius.htm EX-99.1 88298
3 GRAPHIC ex99-1_001.jpg GRAPHIC 15931
  Complete submission text file 0001213900-24-113158.txt   320930

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20241227.xsd EX-101.SCH 3027
5 XBRL LABEL FILE ctxr-20241227_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctxr-20241227_pre.xml EX-101.PRE 22367
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0226161-8k_citius_htm.xml XML 3681
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 241586279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)